Frontline Therapy of Acute Myeloid Leukemia With Lower Intensity Regimens: Where Are We Now and Where Can We Go?

Authors

Jennifer Marvin-Peek
Jason S Gilbert
Daniel A Pollyea
Courtney D DiNardo

Language

English

Publication Date

9-1-2024

Journal

American Journal of Hematology

DOI

10.1002/ajh.27434

PMID

39016070

Abstract

The advent of molecularly targeted therapeutics has transformed the management of patients with acute myeloid leukemia (AML). Particularly for individuals unfit for intensive chemotherapy, lower intensity therapies (LIT) incorporating small molecules have significantly improved patient outcomes. With BCL2, IDH1, IDH2, and FLT3 inhibitors widely used for relapsed AML, combination regimens are now utilized in the frontline. Expansion of these targeted LIT combinations, along with development of novel agents including menin inhibitors, exemplifies the promise of precision medicine. Further understanding of molecular drivers of leukemic transformation and mechanisms of relapse will continue to advance frontline treatment options for patients with AML.

Keywords

Humans, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols, Molecular Targeted Therapy

Published Open-Access

yes

Recommended Citation

Marvin-Peek, Jennifer; Gilbert, Jason S; Pollyea, Daniel A; et al., "Frontline Therapy of Acute Myeloid Leukemia With Lower Intensity Regimens: Where Are We Now and Where Can We Go?" (2024). Faculty, Staff and Student Publications. 5556.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5556